Literature DB >> 29759574

Potentially Lethal Ventricular Arrhythmias and Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy: What Are the Differences Between Men and Women?

Yoshitaka Kimura1, Takashi Noda2, Yosuke Otsuka3, Mitsuru Wada3, Ikutaro Nakajima3, Kohei Ishibashi3, Koji Miyamoto3, Hideo Okamura3, Takeshi Aiba3, Shiro Kamakura3, Teruo Noguchi3, Toshihisa Anzai3, Kazuhiro Satomi4, Hisao Ogawa3, Satoshi Yasuda1, Kengo F Kusano3.   

Abstract

OBJECTIVES: The aim of this study was to assess sex-related differences in sporadic cases of arrhythmogenic right ventricular cardiomyopathy (ARVC).
BACKGROUND: Previous studies have suggested male predominance in ARVC. However, the impact of sex on the heterogeneous clinical profile and prognosis of ARVC were not fully recognized.
METHODS: The study population included 110 patients with ARVC who fulfilled the revised Task Force criteria (median age 48 years [interquartile range (IQR): 36 to 57 years]). All patients were sporadic cases without family history of ARVC. Male patients had a 3:1 predominance (75%). Ninety-seven patients (88%) were considered to have "definite" ARVC based on revised Task Force criteria.
RESULTS: At the initial evaluation, there were no significant sex-related differences in age, 12-lead electrocardiogram findings, late potentials by signal-averaged electrocardiogram, left ventricular ejection fraction, or right ventricular ejection fraction. During a median follow-up of 10.0 years (IQR: 5.2 to 15.6 years), 18 patients died from cardiac causes. Kaplan-Meier analysis, considering patients' lives since birth, revealed that male patients had a significantly higher risk of ventricular tachycardia/ventricular fibrillation than did female patients (56% vs. 90%, p = 0.02), whereas female patients had a significantly higher risk of heart failure (HF) death or heart transplantation (22% vs. 5%, p = 0.002). On multivariate Cox regression analysis, female sex was an independent risk factor for HF death or heart transplantation due to HF (hazard ratio: 6.29, 95% confidence interval: 1.29 to 40.2; p = 0.02).
CONCLUSIONS: Among patients with sporadic ARVC, men had a significantly higher risk of ventricular tachycardia/ventricular fibrillation, whereas women had a significantly higher risk of HF death or heart transplantation due to HF.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  arrhythmogenic right ventricular cardiomyopathy; heart failure; sex; sporadic case; sudden cardiac death

Year:  2016        PMID: 29759574     DOI: 10.1016/j.jacep.2016.02.019

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  4 in total

1.  Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation.

Authors:  Lourdes Vicent; Francisco Méndez-Zurita; Xavier Viñolas; Concepción Alonso-Martín; Carles Moliner Arbòs; Julia Pamies; R Oscar Alcalde; Miriam Juárez; Vanesa Bruña; Carolina Devesa; Iago Sousa-Casasnovas; Francisco Fernández-Avilés; Manuel Martínez-Sellés
Journal:  Heart Vessels       Date:  2019-06-22       Impact factor: 2.037

2.  QRS alternans due to localized intraventricular block during ventricular tachycardia in Uhl's anomaly: a case report.

Authors:  Kosuke Nakasuka; Takashi Noda; Koji Miyamoto; Kengo Kusano
Journal:  Eur Heart J Case Rep       Date:  2019-02-25

3.  Arrhythmogenic right ventricular cardiomyopathy.

Authors:  Yongkeun Cho
Journal:  J Arrhythm       Date:  2018-03-11

4.  Familial Recurrent Myocarditis Triggered by Exercise in Patients With a Truncating Variant of the Desmoplakin Gene.

Authors:  Wolfgang Poller; Jan Haas; Karin Klingel; Jirko Kühnisch; Martina Gast; Ziya Kaya; Felicitas Escher; Elham Kayvanpour; Franziska Degener; Bernd Opgen-Rhein; Felix Berger; Hans-Christian Mochmann; Carsten Skurk; Bettina Heidecker; Heinz-Peter Schultheiss; Lorenzo Monserrat; Benjamin Meder; Ulf Landmesser; Sabine Klaassen
Journal:  J Am Heart Assoc       Date:  2020-05-15       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.